A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein. (PubMed, Hlife) - Oct 24, 2026 - "RV11 showed a strong synergistic effect when combined with two RSV antivirals, an F-targeting small molecular inhibitor ziresovir and a site Ø neutralizing mAb D25 (the parental mAb for nirsevimab). The study extended our knowledge to the neutralizing and protective epitopes of RSV, and the mAb RV11 deserves further development for clinical translation."
Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
|
|
Gang Zou; George Fu Gao; Jian Song; Jim Zhen Wu; Junming Yie; Liang Wang; Lianpan Dai; Lili Xu; Mi Yang; Qihui Wang; Senyu Xu; Sushan Cao; Tong Ma; Yan Chai; Zhao Gao; Zhengde Xie
|